Navigation Links
National Drug Development Accelerator Launched

LENEXA, Kan., Nov. 20 /PRNewswire/ -- KansasBio announced today a bioscience cluster activation initiative to promote the region's human health-care-related bioscience companies that serve the entire drug development continuum. Called the National Drug Development Accelerator (the Accelerator), the alliance comprises companies across Kansas and the Kansas City metropolitan area that represent many of the nation's preferred resources for drug development.

KansasBio says the Accelerator offers a full spectrum of drug development services. From discovery to post market, the alliance of companies offers comprehensive assets to bring pharmaceuticals and biotech drugs to market cost effectively and at a high level of quality.

"Kansas' collection of companies is the answer to the emerging outsourcing trend among pharmaceutical companies," said Angela Kreps, president of KansasBio. "During the last 5 years as pharmaceutical companies have increased outsourcing, and when development budgets are enduring additional scrutiny related to return on investment, our companies are busy bringing the biggest new drugs to market. We will continue to define the value proposition in a tenuous economy."

In the drug development process, where saving one day can mean saving millions of dollars, Kansas service providers have advanced clinical timelines to save pharmaceutical partners days and sometimes weeks. KansasBio cites local companies' responsiveness as one reason that there are 1,950 ongoing clinical trials in the Kansas region -- the fifth highest per capita in the United States. In areas of the state, the number of clinical trials providing access to new treatments has more than doubled during the last 4 years, according to KansasBio.

"The Kansas region has a 30-year history of expertise with the capabilities to go from the chemistry bench to the patient's bedside," said Michael Beckloff, president of Beckloff Associates. "Our cluster represents companies that have helped develop more than 50 of the world's top drugs. We can efficiently move drugs through the development pipeline and help pharmaceutical companies maximize market years and return on investment."

Kansas has a decades-long history of drug development and is home to preferred partners for major pharmaceutical companies. The state has one of the region's greatest geographic concentrations of experienced pharmaceutical development, clinical research and bioscience companies. To learn more about the Accelerator, visit

SOURCE KansasBio
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
6. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
7. Arrow International Files and Mails Definitive Proxy Materials
8. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
9. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
10. Viragen International to Reverse Split Its Common Stock
11. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
Post Your Comments:
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks Associates ... will speak at the TMA 2017 Annual Meeting , October 11 ... in the residential home security market and how smart safety and security ... Parks Associates: ... "The residential security ...
(Date:10/9/2017)... , ... October 09, 2017 , ... The award-winning American ... broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... faced with the challenge of how to continue to feed a growing nation. At ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):